TWO · 6586.TWO
CHO Pharma, Inc.
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
Loading market information…
TWO · 4174.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
OBI Pharma, Inc.’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of -NT$8.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow OBI Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -NT$3.90 |
| NT$14.46M |
| Q4 2024 | Mar 10, 2025 | -NT$6.05 | NT$11.55M |
|---|
| Q3 2024 | Nov 4, 2024 | -NT$4.51 | NT$22.98M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$100.00-NT$3.50 (-3.38%)
CHO Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.66% below the high.
NT$133.50+NT$0.50 (+0.38%)
AP Biosciences Inc’s quoted price sits in the lower half of its reported 52-week range, 43.43% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.
NT$30.95-NT$0.80 (-2.52%)
Senhwa Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.46% below the high.
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$60.40-NT$2.10 (-3.36%)
Shine-On BioMedical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.05% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$11.95-NT$0.60 (-4.78%)
TaiRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.62% below the high.
